Regulatory Updates
🇪🇺 EMA Page 7EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Track global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
Showing 73–84 of 171 articles
Teva's Once-Monthly Schizophrenia Shot Enters EMA Review, Signaling New Treatment Option
ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
ESMO 2025: Key Advances in Non-Muscle-Invasive Bladder Cancer Shape Future Oncology Strategies
Datroway and Trodelvy Vie for First-Line TNBC Dominance Amidst Evolving Treatment Landscape
Idorsia's C. difficile Vaccine Shows Continued Positive Clinical Progress
Ascentage Pharma's Olverembatinib Update: Insights from ASCO 2026
OS Therapies Acquires Full IP Rights to OST-HER2 for $8M
Bio/Pharma Outlook 2026: Regulatory Updates and Implications
FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights
Rethinking QA/QC at The Future of Bio/Pharmaceutical Analysis 2026
International School of Clinical Oncology Annual Congress 2026: Key Insights
Ascentage Pharma's 17 Clinical Advances at EHA 2026